| DB ID | MyCo_3450 |
| Title | Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients |
| Year | 2021 |
| PMID | 33912176 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | This study was approved by the Ethics Committee of Tongji Hospital, Tongji M e d i c a l C o l l e g e , H u a z h o n g U n i v e r s i t y o f S c i e n c e and Technology. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CD4 |
| Biomarker Full Name | CD4 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | A total of 40 PJP patients (26 males, 14 females; medium age, 52 years; IQR, 23-73 years) were included in the study. Another 40 patients who received immunosuppressive treatment but without signs of infectious diseases, with matched gender, age, and underlying conditions as PJP patients, were enrolled as control group (non-PJP). |
| Cohort No. | 40 Patients and 40 control |
| Age Group | 44-61 |
| P Value | None |
| Sensitivity | 0.95 |
| Specificity | 0.8 |
| Positive Predictive Value | 0.8261 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Flow Cytometry Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Flow Cytometry Analysis |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
